Borrelpraat of onderzoek?
Geplaatst: 26 okt 2017, 12:34
Levothyroxine dose tweaks don't alter symptoms in hypothyroidism
https://www.medscape.com/viewarticle/887558
Kan gewoon wel kwaad worden om zo'n onderzoek met die eeuwige zinloze vragenlijsten ...
Enkele passages
Alterations of thyroid hormone levels through levothyroxine dose adjustments to lower and higher levels within normal reference ranges and even to subclinical hypothyroid levels show no significant effects on quality-of-life, mood, and cognitive-function measures in a double-blind, randomized study.
"Clinicians should set reasonable expectations for hypothyroid patients who request increased levothyroxine doses based on nonspecific quality of life, mood, or cognitive symptoms," senior author Mary H Samuels, MD, of the department of endocrinology, diabetes, and clinical nutrition, Oregon Health & Science University, Portland, told Medscape Medical News.
"These symptoms are unlikely to be related to levothyroxine doses and may not improve when doses are changed," she stressed.
In response to audience suggestions of various other factors that could play a role in symptoms, she agreed, "There's no question there could be a myriad of unmeasured variables.
"Further research in older subjects, men, and subjects with specific symptomatology, low T3 levels, and/or functional polymorphisms would be valuable," she added noting that this new study nevertheless importantly moves the field forward by providing a look at the issue in a randomized group.
"This is the first placebo-controlled, blinded study to show that altering levothyroxine doses in hypothyroid patients does not affect quality of life, mood, or cognitive function using extensive and sensitive measures of these outcomes, which are all common symptoms in treated hypothyroid patients," she stressed.
Catherine A Dinauer, MD, a pediatric endocrinologist and clinician at the Yale Pediatric Thyroid Center, in New Haven, Connecticut, who comoderated the session, agreed that the study sheds important light on responses to levothyroxine doses.
"I think these are interesting data because there is this sense among patients that the levothyroxine dose really affects how they feel," she said.
"This essentially turns that on its head and [suggests] it's not really clear why patients are potentially not doing well. I think it will be interesting to see more data on this."
https://www.medscape.com/viewarticle/887558
Kan gewoon wel kwaad worden om zo'n onderzoek met die eeuwige zinloze vragenlijsten ...
Enkele passages
Alterations of thyroid hormone levels through levothyroxine dose adjustments to lower and higher levels within normal reference ranges and even to subclinical hypothyroid levels show no significant effects on quality-of-life, mood, and cognitive-function measures in a double-blind, randomized study.
"Clinicians should set reasonable expectations for hypothyroid patients who request increased levothyroxine doses based on nonspecific quality of life, mood, or cognitive symptoms," senior author Mary H Samuels, MD, of the department of endocrinology, diabetes, and clinical nutrition, Oregon Health & Science University, Portland, told Medscape Medical News.
"These symptoms are unlikely to be related to levothyroxine doses and may not improve when doses are changed," she stressed.
In response to audience suggestions of various other factors that could play a role in symptoms, she agreed, "There's no question there could be a myriad of unmeasured variables.
"Further research in older subjects, men, and subjects with specific symptomatology, low T3 levels, and/or functional polymorphisms would be valuable," she added noting that this new study nevertheless importantly moves the field forward by providing a look at the issue in a randomized group.
"This is the first placebo-controlled, blinded study to show that altering levothyroxine doses in hypothyroid patients does not affect quality of life, mood, or cognitive function using extensive and sensitive measures of these outcomes, which are all common symptoms in treated hypothyroid patients," she stressed.
Catherine A Dinauer, MD, a pediatric endocrinologist and clinician at the Yale Pediatric Thyroid Center, in New Haven, Connecticut, who comoderated the session, agreed that the study sheds important light on responses to levothyroxine doses.
"I think these are interesting data because there is this sense among patients that the levothyroxine dose really affects how they feel," she said.
"This essentially turns that on its head and [suggests] it's not really clear why patients are potentially not doing well. I think it will be interesting to see more data on this."